Patients with liver cirrhosis exhibit several features of gut dysfunction which may contribute
to the development of cirrhosis complications as well as have an impact on nutritional status …

Acid suppressive therapy, in the form of proton pump inhibitor (PPI), is widely used in
cirrhotic patients, often in indications which are not clearly justified. PPI facilitates enteric …

Objective. Gastrointestinal symptoms can lead to decreased food intake and thereby
increased morbidity. There is a general lack of data on the prevalence of gastrointestinal …

The presence of cirrhosis increases the mortality of patients with peptic ulcer bleeding
(PUB). Both acute variceal bleeding (AVB) and PUB are associated with substantial mortality …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death, as
few patients can be treated with currently available curative local modalities. In patients with …

Abstract Background and Aim Upper gastrointestinal bleeding (UGIB) is a serious
complication of portal hypertension in cirrhotic patients. The objective of this study is to …

Background The frequency of gastrointestinal ulcerations is higher in cirrhotic patients than
in the normal population. It has been shown that pioglitazone exhibits gastroprotective …

Background: Understanding of the gut-liver axis is important for the up-to-date management
of liver cirrhosis, and changes of intestinal functions form the core of this interesting research …

Abstract Proton Pump Inhibitors (PPI) are very effective in inhibiting acid secretion and are
extensively used in many acid related diseases. They are also often used in patients with …

Background Few large population‐based studies have compared the occurrence of peptic
ulcer bleeding (PUB) in cirrhotic and noncirrhotic patients. Aims To investigate if cirrhotic …